Robert Lupinacci

3.5k total citations · 2 hit papers
35 papers, 2.4k citations indexed

About

Robert Lupinacci is a scholar working on Epidemiology, Infectious Diseases and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Robert Lupinacci has authored 35 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Epidemiology, 14 papers in Infectious Diseases and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Robert Lupinacci's work include Pneumonia and Respiratory Infections (14 papers), Antifungal resistance and susceptibility (14 papers) and Respiratory viral infections research (11 papers). Robert Lupinacci is often cited by papers focused on Pneumonia and Respiratory Infections (14 papers), Antifungal resistance and susceptibility (14 papers) and Respiratory viral infections research (11 papers). Robert Lupinacci collaborates with scholars based in United States, Israel and Australia. Robert Lupinacci's co-authors include Carole A. Sable, Nicholas A. Kartsonis, Arnaldo Lopes Colombo, John R. Perfect, Robert F. Betts, Coleman Rotstein, Luis Thompson-Moya, Michael Bourque, Hedy Teppler and Johan Maertens and has published in prestigious journals such as New England Journal of Medicine, Blood and PEDIATRICS.

In The Last Decade

Robert Lupinacci

34 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis

2002 990 citations Robert F. Betts, Coleman Rotstein et al. New England Journal of Medicine profile →
Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia

2004 644 citations Thomas J. Walsh, Hedy Teppler et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Lupinacci United States	16	2.0k	1.7k	355	249	230	35	2.4k
Laura Kovanda United States	27	2.5k 1.2×	2.0k 1.2×	183 0.5×	299 1.2×	297 1.3×	57	2.8k
Juergen Prattes Austria	29	2.0k 1.0×	1.7k 1.0×	88 0.2×	265 1.1×	284 1.2×	79	2.3k
R.A. Barnes United Kingdom	17	1.3k 0.7×	1.1k 0.6×	109 0.3×	135 0.5×	169 0.7×	26	1.6k
Luis Thompson-Moya Chile	8	1.0k 0.5×	842 0.5×	117 0.3×	101 0.4×	128 0.6×	10	1.2k
Jack D. Sobel United States	12	1.6k 0.8×	1.2k 0.7×	130 0.4×	44 0.2×	193 0.8×	21	2.0k
Hetty Waskin United States	24	1.5k 0.8×	1.5k 0.9×	167 0.5×	90 0.4×	151 0.7×	46	2.3k
P. K. Sharkey United States	11	1.2k 0.6×	1.3k 0.7×	96 0.3×	151 0.6×	88 0.4×	13	1.6k
Mabel Aoun Lebanon	19	744 0.4×	744 0.4×	357 1.0×	68 0.3×	156 0.7×	61	1.4k
Michele Wible United States	9	879 0.4×	786 0.5×	72 0.2×	84 0.3×	91 0.4×	18	1.1k
Kim M. Strohmaier United States	19	913 0.5×	454 0.3×	75 0.2×	77 0.3×	114 0.5×	28	1.2k

Countries citing papers authored by Robert Lupinacci

Since Specialization

Citations

This map shows the geographic impact of Robert Lupinacci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Lupinacci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Lupinacci more than expected).

Fields of papers citing papers by Robert Lupinacci

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Lupinacci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Lupinacci. The network helps show where Robert Lupinacci may publish in the future.

Co-authorship network of co-authors of Robert Lupinacci

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Lupinacci. A scholar is included among the top collaborators of Robert Lupinacci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Lupinacci. Robert Lupinacci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mukai, Yuki, Robert Lupinacci, Stephen R. Marder, et al.. (2024). Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial. Schizophrenia Research. 270. 37–43. 10 indexed citations

Martinón‐Torres, Federico, Jacek Wysocki, Leszek Szenborn, et al.. (2023). A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1). Vaccine. 41(21). 3387–3398. 15 indexed citations

Benfield, Thomas, Piero Valentini, Ron Dagan, et al.. (2023). Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2). Vaccine. 41(15). 2456–2465. 15 indexed citations

Lupinacci, Robert, Richard Rupp, Orasri Wittawatmongkol, et al.. (2023). A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED). Vaccine. 41(5). 1142–1152. 26 indexed citations

Wilck, Marissa B., Shaun Barnabas, Kulkanya Chokephaibulkit, et al.. (2023). A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV. AIDS. 37(8). 1227–1237. 2 indexed citations

Quinn, Charles T., Richard T. Wiedmann, Daniel Jarovsky, et al.. (2022). Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study. Blood Advances. 7(3). 414–421. 6 indexed citations

Bili, Androniki, Scott Dobson, Wanatpreeya Phongsamart, et al.. (2022). A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION). Vaccine. 41(3). 657–665. 10 indexed citations

Herring, W. Joseph, Tiffany Woo, Christopher Assaid, et al.. (2017). Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies. Journal of Clinical Anesthesia. 41. 84–91. 33 indexed citations

Chabi, Almira, Rohit Varma, James C. Tsai, et al.. (2012). Randomized Clinical Trial of the Efficacy and Safety of Preservative-free Tafluprost and Timolol in Patients With Open-Angle Glaucoma or Ocular Hypertension. American Journal of Ophthalmology. 153(6). 1187–1196. 39 indexed citations

10.

DiNubile, Mark J., Peter Sklar, Robert Lupinacci, & Joseph J. Eron. (2012). Paradoxical Interpretations of Noninferiority Studies: Violating the Excluded Middle. Future Virology. 7(11). 1055–1063. 2 indexed citations

11.

Ngai, Angela, Michael Bourque, Robert Lupinacci, Kim M. Strohmaier, & Nicholas A. Kartsonis. (2011). Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: a brief report. International Journal of Antimicrobial Agents. 38(6). 540–544. 21 indexed citations

12.

Ryan, Desmon̄d, Robert Lupinacci, & Nicholas A. Kartsonis. (2011). Efficacy and safety of caspofungin in obese patients. Medical Mycology. 49(7). 1–7. 12 indexed citations

13.

DiNubile, Mark J., Kim M. Strohmaier, Robert Lupinacci, et al.. (2008). Efficacy and safety of caspofungin therapy in elderly patients with proven or suspected invasive fungal infections. European Journal of Clinical Microbiology & Infectious Diseases. 27(8). 663–670. 6 indexed citations

14.

DiNubile, Mark J., Robert Lupinacci, Kim M. Strohmaier, Carole A. Sable, & Nicholas A. Kartsonis. (2007). Invasive candidiasis treated in the intensive care unit: Observations from a randomized clinical trial. Journal of Critical Care. 22(3). 237–244. 36 indexed citations

15.

Pauw, B.E. de, Carole A. Sable, Thomas J. Walsh, et al.. (2006). Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study. Transplant Infectious Disease. 8(1). 31–37. 28 indexed citations

16.

Betts, Robert F., Axel Glasmacher, Johan Maertens, et al.. (2005). Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer. 106(2). 466–473. 56 indexed citations

17.

Walsh, Thomas J., Hedy Teppler, Gerald R. Donowitz, et al.. (2004). Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia. New England Journal of Medicine. 351(14). 1391–1402. 644 indexed citations breakdown →

18.

DiNubile, Mark J., Robert Lupinacci, Rayanne S. Berman, & Carole A. Sable. (2002). Response and Relapse Rates of Candidal Esophagitis in HIV-Infected Patients Treated with Caspofungin. AIDS Research and Human Retroviruses. 18(13). 903–908. 27 indexed citations

19.

Villanueva, Álvaro, Eduardo Gotuzzo, Eduardo Arathoon, et al.. (2002). A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. The American Journal of Medicine. 113(4). 294–299. 211 indexed citations

20.

Betts, Robert F., Coleman Rotstein, Arnaldo Lopes Colombo, et al.. (2002). Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis. New England Journal of Medicine. 347(25). 2020–2029. 990 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact